Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in The Ensign Group to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in The Ensign Group between February 10, 2022 and June 18, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Ensign Group, Inc. ("“The Ensign Group” or the “Company”) (NASDAQ: ENSG) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012469497/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Ensign's business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (2) Ensign's abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (3) Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients; (4) Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (5) Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents; (6) Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; (7) Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model; and (8) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On June 8, 2026, Hunterbrook Media published a report entitled "Ensign: The Nursing Home Empire Built on Fatal Neglect," stating that "Ensign's business model relies on delivering inadequate care to patients while gaming data on quality[.] Patients are dying." On this news, Ensign's stock price fell $13.88, or 8.15%, to close at $156.42 per share on June 8, 2026.

On June 11, 2026, Muddy Waters Research published a report entitled "Ensign: Deceiving the Government at Estimated ~20% of Facilities," concluding that Ensign engages in a systematic scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, the facilities. On this news, Ensign's stock price fell $4.52, or 2.98%, to close at $147.13 on June 11, 2026.

On June 18, 2026, Hunterbrook issued a follow up report entitled "New: Patients Hungry in Ensign Facilities," adding new firsthand evidence of resident hunger, payroll falsification, understaffing, and staff licensing issues. On this news, Ensign's stock price fell $2.19, or 1.4%, to close at $153.65 per share on June 18, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding The Ensign Group’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the The Ensign Group class action, go to www.faruqilaw.com/ENSG or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the The Ensign Group Securities Class Action Lawsuit:

What is the The Ensign Group securities fraud lawsuit about?

The lawsuit alleges that The Ensign Group, Inc. made materially false and misleading statements about its business, operations, and prospects throughout the Class Period. Specifically, the complaint alleges that Ensign's business model depends on the systematic neglect of elderly residents, including by allegedly failing to provide adequate food, medical attention, and basic toiletries, resulting in resident deaths. The lawsuit further alleges that Ensign allegedly defrauded Medicare and Medicaid by accepting federal funds designated for high-needs patients while neglecting those same patients, falsified certified nursing assistant staffing hours, and engaged in an alleged illegal scheme to rent administrator licenses from individuals not present at or managing its facilities. The complaint also alleges that Ensign used self-reporting mechanisms to conceal this alleged pattern of neglect and materially understated the reputational and litigation risks arising from its alleged business practices.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, inclusive, may be eligible to participate in this lawsuit. Participation is not limited to those who seek appointment as lead plaintiff; any eligible class member may share in any recovery that may be obtained. Investors are encouraged to review their trading records for purchases of Ensign securities during this period to determine whether they may qualify as a class member.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed class member who serves as a representative party on behalf of all class members and works with class counsel to direct the litigation. The lead plaintiff typically has the largest financial interest in the relief sought and is required to adequately represent the interests of the class. Investors who wish to seek appointment as lead plaintiff must file a motion with the court by the applicable lead plaintiff deadline. Importantly, investors need not serve as lead plaintiff to participate in the class and share in any recovery that may be obtained; class members who do not seek appointment may still be eligible to benefit from any judgment or settlement.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased The Ensign Group securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261012469497/en/